Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis

Immune checkpoint inhibitors (ICIs) have made a breakthrough in the systemic treatment for metastatic triple-negative breast cancer (TNBC) patients. However, results of phase II and III clinical trials assessing ICIs plus chemotherapy as neoadjuvant treatment were controversial and conflicting. We p...

Full description

Bibliographic Details

Published in:	Cells
Main Authors:	Alessandro Rizzo, Antonio Cusmai, Raffaella Massafra, Samantha Bove, Maria Colomba Comes, Annarita Fanizzi, Lucia Rinaldi, Silvana Acquafredda, Gennaro Gadaleta-Caldarola, Donato Oreste, Alfredo Zito, Francesco Giotta, Vito Lorusso, Gennaro Palmiotti
Format:	Article
Language:	English
Published:	MDPI AG 2022-06-01
Subjects:	breast cancer pembrolizumab atezolizumab durvalumab immunotherapy neoadjuvant
Online Access:	https://www.mdpi.com/2073-4409/11/12/1857